Document is current

Article History

Received: 17 March 2025

Accepted: 24 November 2025

First Online: 12 December 2025

Declarations

:

: Prajakta Badri, Kiranmai Kolachana, Anh Duong, Maxwell Lasko, Tirtha Nandi, Nitin Mehrotra, and Gabriel J. Robbie are or were Alnylam Pharmaceutical employees and may hold Alnylam stocks or options.

: P.B., K.K., A.D., M.L., and T.N. contributed to the data analyses for this manuscript, interpretation of results, and writing and reviewing of the manuscript. N.M. and G.R. contributed to the study design, interpretation of results, and writing and reviewing of the manuscript.

: The datasets generated during and/or analyzed during the current study are not publicly available owing to likelihood of patient identification or other feasibility issues, but may be available from the corresponding author on reasonable request and upon approval by Alnylam.

: This study was conducted in accordance with the Good Clinical Practice Guideline as defined by the International Conference on Harmonization, the Declaration of Helsinki, and all applicable federal and local regulations. The study was approved by independent institutional review boards.

: Not applicable

: Written informed consent was obtained from each subject before any study-related procedures were performed.